Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.

Ann Oncol · 2017 · PMC5834040 · PMID 29045520

Europe PMC DOI

hedged sentences

0.2400

closest p · 4.8× alpha

0.2400

boldest claim

The sentences

did not reach statistical significanceP = 0.24not close (p > 0.1)

Kaplan–Meier analysis showed a 5.5-month increase in median OS with cabozantinib versus placebo (26.6 versus 21.1 months) although the difference did not reach statistical significance [stratified hazard ratio (HR), 0.85; 95% confidence interval (CI), 0.64–1.12; P = 0.24].

also in 111,027 other papers

showed a trendno p-value reported

Subgroup analysis of patients harboring RAS mutations showed a trend toward improved OS (HR, 0.37; 95% CI, 0.10–1.42) and PFS (HR, 0.15; 95% CI, 0.02–1.10).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.